14:10 – 14:15
14:15 – 14:35
14:35 – 14:55
14:55 – 15:15
15:15 – 15:35
論壇議程總覽
2025 創新科技論壇
2025 Innovation Forum Agenda
Date July 23-25, 2025
Venue July 23 Room 701C, 7F, TaiNEX2
July 24-25 Room 401, 4F, TaiNEX1
Day 1 - Wednesday, July 23Room 701C, 7F, TaiNEX2
Day 2 - Thursday, July 24Room 401, 4F, TaiNEX1
Day 3 - Friday, July 25Room 401, 4F, TaiNEX1
14:10 – 15:40
Session A-1 – New Therapeutic Modalities
Session A-1 is a deep dive into the latest therapeutic innovations, showcasing next-generation approaches reshaping modern medicine. Speakers will present translational breakthroughs in targeted therapies, as well as cutting-edge developments in nucleic acid therapeutics, spotlighting their potential in precision medicine. Other topics covered include accelerating therapeutic pipelines from lab to market, and the latest oncology and hematology therapies. This session promises a dynamic exchange on how novel modalities are redefining treatment landscapes and improving patient care worldwide.
16:00 – 17:30
Session A-2 – Gene and Cell Therapies- Advanced Manufacture and Beyond
Session A-2 explores the rapidly-evolving frontier of gene and cell therapy manufacturing, focusing on innovation, scalability, and regulatory alignment. Topics covered will include Taiwan’s strategic role in next-gen biomanufacturing; technical breakthroughs driving production efficiency and therapeutic consistency; addressing the balance between fast-paced technology and regulatory rigor; and an examination of the field of clinical translation and real-world applications. This session promises a comprehensive look at how manufacturing is adapting to meet the complex demands of advanced therapies.
16:05 – 16:20
16:20 – 16:35
16:35 – 16:50
16:50 – 17:05
17:05 – 17:30
Panel Discussion
Moderator:
Panelists:
- Ann Lee, Chief Technical Officer, Prime Medicine
- Snehal Patel, Chief Technical Officer, Sana Biotechnology
- Matthew Hewitt, Vice President, CTO Manufacturing Business Division, Charles River Laboratories
- Jeffrey Chou, Senior Vice President, Clinical Science, Iovance Biotherapeutics
09:00 – 10:30
Session A-3 – AI & Translational Medicine
Session A-3 spotlights the transformative role of AI in accelerating translational medicine and drug discovery. Speakers will uncover how to better integrate AI in biomedical research; how machine learning enhances cross-dataset drug discovery; AI’s potential in population-level healthcare; and an examination of data-driven public health strategies. Join us as thought leaders demonstrate how AI is reshaping research, improving precision, and bridging discovery to clinical application in unprecedented ways.
09:00 – 09:05
09:05 – 09:25
09:25 – 09:45
09:45 – 10:05
10:05 – 10:30
Panel Discussion
Moderator:
Panelists:
- Huey-Kang Sytwu, President, National Health Research Institutes
- Lani Wu, Professor, University of California, San Francisco
- Brian Bradbury, Vice President, Observational Research, Amgen
- Feng-Chi Chen, Executive Director, Forum & Deputy Director and Investigator, Institute of Population Health Sciences, National Health Research Institutes
10:40 – 12:15
Session A-4 – Taiwan BIO Awards-Successful Stories
Join us as this year's Taiwan BIO Awards winners across all categories present their companies and innovations, and unveil the secrets to their success! Congratulations to all this year's well-deserved winners.
10:40 – 12:15
Sharing the Experience of Biotech Success 2025 Taiwan BIO Awards Winners:
- Outstanding Company of the Year
- Emerging Company of the Year
- Startup of the Year
-
11:20-11:25
JelloX Biotech Inc.
Yen-Yin Lin, CEO -
11:25-11:30
Fecula Biotech Co., Ltd.
Miles Chen, CEO
- Innovation of the Year
-
11:55-12:15
Networking
12:25-13:50
Session A-5 – Decision Making on Outsourcing in the Current Changing Economic Environment
Session A-5 will explore the strategic decision-making process behind outsourcing biologics manufacturing, comparing perspectives from a Taiwanese-based company and an American-based company. Speakers will examine key drivers such as cost efficiency, regulatory considerations, supply chain logistics, and access to specialized expertise. The discussion will highlight how cultural, economic, and policy differences influence outsourcing strategies across regions. Attendees will gain insight into global trends and best practices shaping the future of biologics production.
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
13:15 – 13:45
Panel Discussion and Q&A
Moderator:
- Stephen Lam, Chief Executive Officer, Bora Biologics
Panelists:
- Jennifer Ho, Vice President of Research and Clinical Development, Shine-On BioMedicals
- Vu Truong, CEO, Aridis Pharmaceuticals
- Marc Goemans, Chief Commercial Officer, Bora Biologics
13:45 – 13:50
Closing Remarks
- Stephen Lam, Chief Executive Officer, Bora Biologics
14:10 – 15:30
Session A-6 – Innovative Developments and Cross-Disciplinary Applications of Antibody Derivatives
Session A-6 will explore the expanding frontier of antibody derivatives, showcasing how innovation is unlocking new therapeutic and diagnostic possibilities. Experts will uncover cutting-edge advances in antibody-drug conjugates, bispecifics, nanobodies, and engineered antibodies, highlighting their enhanced specificity, efficacy, and versatility. The session will also examine how these novel formats are being applied beyond oncology, including in infectious diseases and autoimmune disorders. With an emphasis on cross-sector collaboration and real-world applications, this session promises a comprehensive view of how antibodies and antibody derivatives are delivering solutions to complex clinical challenges.
14:15 – 14:40
14:40 – 15:05
15:40 – 17:10
Session A-7 – Innovative Developments and Cross-Disciplinary Applications of Antibody Derivatives
A follow on from Session A-6, again on fast-evolving antibody derivative technologies and their transformative potential across a wide range of therapeutic areas.
15:40 – 16:05
16:05 – 16:30
T-cube T Cell Engagers－Gearing Up to Meet Unmet Medical Challenges
16:30 – 17:10
Panel Discussion
Moderator:
- Lee-Cheng Liu, Founder, Chairman & President, EirGenix
- Heidi Wang, Chief Executive Officer, OBI Pharma
Panelists:
- Manuel Sanz, COO, Oncomatryx Biopharma
- Edward Y. H. Hsieh, R&D VP, Formosa Laboratories
- Oshra Betzer, COO and Co-Founder, Nanocarry Therapeutics
- Ming-Tang Chen, Senior Director, PharmaEssentia Innovation Research Center
- Jeng Her, CEO, AP Biosciences
- Yen-Ming Hsu, CEO, AB Biosciences
- David Teng-Yi Huang, Senior Director of Medicinal Chemistry & ADC Enabling Technologies, OBI Pharma
09:00 – 10:30
Session A-8 – Novel ADC-based Target Therapy
Session A-8 focuses on the rapid evolution of antibody-drug conjugates (ADCs) as a next-generation targeted therapy category. Experts will highlight innovations in linker chemistry, payload design, and tumor-specific targeting, leading to impressive ADC efficacy and safety profiles. The session will explore how novel ADCs are expanding beyond oncology into new therapeutic areas, offering highly selective treatment options with minimized systemic toxicity. Join us for this important session as leading experts in this field underscore ADCs’ growing role in redefining targeted therapies and improving patient outcomes.
09:05 – 09:25
09:25 – 09:45
09:45 – 10:05
10:10 – 10:30
Panel Discussion
Moderator:
Panelists:
10:45 – 12:15
Session A-9 – Smart HealthCare
Session A-9 will explore the transformative impact of smart healthcare technologies on the entire healthcare delivery spectrum, beginning with a discussion on reshaping the future of healthcare through "Gen" medicine, emphasizing precision therapies and personalized treatments. Experts from the TMU Health System will share insights into AI applications in clinical practice, highlighting advancements in diagnostics, treatment planning, and patient monitoring. The session will also address the critical role of AI-driven cybersecurity in safeguarding healthcare systems. A regulatory overview will be provided on the latest FDA guidelines for smart healthcare and AI-based medical devices, ensuring compliance and innovation in this rapidly evolving field.
10:45 – 10:50
10:50 – 11:05
11:05 – 11:20
11:20 – 11:35
11:35 – 11:50
11:50 – 12:15
12:25 – 13:50
Session A-10 – Exploring the Future of Precision Health in Taiwan
With the rapid advancement of next-generation sequencing (NGS) technologies, national-scale whole genome sequencing (WGS) initiatives are transforming healthcare, public health, and drug development. This session explores international efforts in building human WGS databases, the strategic roles of key industry players, and the real-world impact of WGS on precision medicine and therapeutics. Experts from leading technology and pharmaceutical companies, along with clinical and regulatory professionals, will provide insights into how WGS data is shaping the future of personalized healthcare.
12:25 – 12:35
Opening Remarks
- Dr. Chien-Cheng Tai, Senior Technical Specialist of the Department of Industrial Technology, Ministry of Economic Affairs (MOEA)
- Jeffrey Dutton, Commercial Officer, American Institute in Taiwan (AIT)
- Eric Y. Chuang, Vice President of ITRI, and General Director, Biomedical Technology and Device Research Laboratories (BDL), ITRI
Group Photo
12:35 – 13:23
Leveraging WGS Data in Drug Discovery and Development
AI-Driven Multi-Omics and Biobank Partnerships: Accelerating Innovation in Drug Discovery
Leveraging Multi-omiccs Big Data and Artificial Intelligence for Precision Health
Taiwan to LA: Catalyzing the Future of Biotech and AI-Driven Health Innovation
13:23 – 13:50
Panel Discussion: From Global Vision to Local Possibilities: Exploring the Future of WGS in Taiwan
Moderator:
Panelists:
- Guillermo Del Angel, Executive Director, Rare Disease Therapy Area Head, Center for Genomics Research, AstraZeneca
- Kyle Kai-How Farh, Vice President and Distinguished Scientist, Artificial Intelligence, Illumina
- Wayne Huey-Herng Sheu, Vice President, National Health Research Institutes
- Dave Whelan, Venture Consultant and Chief Business Officer, Wavemaker 360 Health and Big4Bio
14:10 – 17:15
Session A-11 – Special Session: Digital Health
Session A-11 will provide a comprehensive overview of the latest advancements and trends in digital health, focusing on innovative technologies shaping the future of healthcare delivery. Experts will examine the integration of wearables, mobile health apps, telemedicine, and AI-driven solutions to enhance patient care, improve outcomes, and optimize healthcare systems. The session will face up to challenges such as data privacy, regulatory hurdles, and ensuring equitable access to digital health tools. Special attention will be given to the potential of digital health in transforming chronic disease management, remote patient monitoring, and personalized treatments. Don't miss what promises to be a pivotal discussion of digital health ecosystems, both now and in the future.
14:10 – 14:20
14:20 – 14:40
14:40 – 15:00
15:00 – 15:15
15:15 – 15:30
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
16:15 – 16:30
16:30 – 16:45
16:45 – 17:15
Panel Discussion
Moderator:
- Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association
- Johnsee Lee, Chairman of BIO Asia–Taiwan 2025
Panelists:
- Stan Shih, Chairman, StanShih Foundation; Co-founder & Honorary Chairman, Acer Group
- Paru Deshpande, VP, Health Technologies, Imec vzw
- Yommei Yanagiba, Head of Business Development & Treasurer, GE HealthCare China
- Edward Hsu, President and Chief Medical Officer, Acer Medical
- Ed Deng, Co-Founder and CEO, Health2Sync
13:30 – 15:35
Session A-12 – Alzheimer’s Disease Forum
Session A-12 will provide a comprehensive exploration of Alzheimer’s Disease through the perspective of government, caregivers, academia, and industry. Featuring 13 local and international speakers, the session will deliver insights on current disease management, local policy initiatives, and the evolving landscape of treatment development--from historical milestones to next-generation therapeutics. Session speakers will also highlight advances in diagnostic imaging including PET, discuss key pathological indications, and consider the real-world impact on patients and caregivers. This multi-perspective dialogue aims to foster collaboration and innovation toward more effective interventions and support systems in the fight against Alzheimer’s Disease. See you there!
13:30 – 13:35
13:35 – 13:40
13:40 – 13:50
Landscape and National Policy Framework for Dementia in Taiwan
- TBD
13:50 – 14:00
14:00 – 14:15
14:15 – 14:20
14:20 – 14:35
14:35 – 14:50
14:50 – 15:00
15:00 – 15:05
15:05 – 15:10
15:10 – 15:20
15:20 – 15:30
15:30 – 15:35
Session Synopsis